Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianwei Qutong Pellets (健胃祛痛微丸) is a Traditional Chinese Medicine (TCM) candidate developed by Hunan Fangsheng Pharmaceutical for the treatment of chronic non-atrophic gastritis. It is specifically designed for patients presenting with the TCM syndrome of 'Spleen and Stomach Qi Deficiency with Damp-Heat and Stasis' (脾胃气虚兼湿热瘀滞证). The drug is formulated as pellets (micro-pills) for oral administration, a delivery format intended to optimize the release and absorption of its herbal components. Jianwei Qutong Pellets aims to alleviate gastric pain and improve mucosal health by addressing underlying patterns of deficiency and stagnation. Clinical development, including trial CTR20150856, has focused on evaluating its safety and efficacy while exploring optimal dosing for subsequent Phase III trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianwei Qutong Pellets.